新华制药(000756) - 2022 Q4 - 年度财报

Financial Performance - The fully diluted earnings per share for 2022 is RMB 0.6102 per share, calculated based on the latest total share capital after the exercise of stock options[8]. - In 2022, the company achieved a total revenue of RMB 7.50 billion, representing a year-on-year increase of 14.37%[115]. - The total revenue for 2022 reached RMB 7,502,987,102.09, representing a year-on-year increase of 27.15% compared to RMB 5,465,656,107.15 in 2021[143]. - The net profit attributable to shareholders of the listed company reached RMB 411,193,683.53, reflecting a growth of 17.97% from RMB 348,548,495.99 in the previous year[177]. - The net profit after deducting non-recurring gains and losses was RMB 378,636,297.99, a significant increase of 29.97% from RMB 291,335,832.10 in 2021[177]. - The basic earnings per share rose to RMB 0.62, representing a 10.71% increase from RMB 0.56 in the previous year[177]. - The gross profit margin for the overall business was 14.37%, slightly up from 14.19% in the previous year[143]. - The revenue from the analgesic raw materials segment was RMB 3,171,564,382.95, showing a growth of 30.70% from RMB 2,198,020,297.84 in the previous year[143]. - The sales revenue of the top 10 strategic formulations grew by 30% year-on-year, with fish oil soft capsules exceeding RMB 10 million in sales[131]. - The international formulations and contract manufacturing sales increased by 88% year-on-year[131]. Shareholder Information - The top ten shareholders at the end of the reporting period include Hualu Holdings Group Co., Ltd. with 204,864,092 shares and Hong Kong Central Clearing Limited with 193,302,927 shares[12]. - The company proposed a dividend of RMB 0.20 per share for the year-end 2022, subject to approval at the annual general meeting[130]. - The company has a total of 1,284,620 shares held by key management personnel as of December 31, 2022, an increase from 826,270 shares in the previous year[39]. Management and Governance - The company has undergone changes in its board and management, with Xu Wenhui appointed as the general manager and executive director on September 19, 2022[28]. - The company’s board of directors held a total of 9 meetings in the year, with all independent directors attending[45]. - The board of directors has a clear responsibility to create value for shareholders and ensure effective management of the company[56]. - The company has established a performance evaluation and incentive mechanism for senior management[76]. - The company has implemented a board diversity policy to enhance the skills and perspectives of its members, focusing on various criteria including business experience and gender[88]. - The audit committee recommended the reappointment of the auditing firm for the year 2023 after reviewing the audited accounts and performance announcement for 2022[34]. Financial Reporting and Compliance - The company does not have any discrepancies between the financial indicators disclosed in the annual report and those in the quarterly and semi-annual reports[9]. - The company's financial statements for the year 2022 were prepared in accordance with the accounting policies and standards set by the Ministry of Finance of China, with no significant misstatements or omissions found[34]. - The company’s internal control over financial reporting is deemed effective, ensuring the reliability of financial statements[34]. - The company confirmed that all directors are entitled to seek independent professional advice at the company's expense, promoting informed decision-making[87]. - The internal control audit report was published on March 27, 2023, indicating ongoing compliance with regulatory requirements[81]. Employee and Training Initiatives - As of December 31, 2022, the total number of employees was 6,781, with 3,733 in production, 920 in sales, and 617 in engineering and technology[43]. - The company completed 65 training projects in 2022, training a total of 2,378 employees, enhancing their skills and capabilities[44]. - The company has established a comprehensive training system to improve employee capabilities and ensure effective management operations[44]. Research and Development - The company received 7 new product approvals for formulations and 5 consistency evaluation approvals in 2022, marking significant progress in drug innovation[106]. - The company has 28 drugs under research for consistency evaluation, with 8 products currently in the review queue at CDE[159]. - The company is accelerating the research and development of series of drugs including ibuprofen, high molecular drugs, and steroid hormones[136]. - Research and development expenses for 2022 were RMB 345,658,511.77, a slight increase of 1.26% from RMB 341,367,394.20 in 2021[146]. Cash Flow and Investments - The net cash inflow from operating activities increased significantly due to expanded sales scale and increased customer prepayments[149]. - The company’s cash and cash equivalents rose by RMB 244 million due to funds raised from a non-public offering and increased customer prepayments[153]. - The net cash flow from operating activities surged by 192.62% to RMB 758,240,601.50, compared to RMB 259,116,960.17 in 2021[177]. - The company reported a total initial investment cost of RMB 21,225,318.00 in securities, with a current book value of RMB 173,490,512.00[1]. Market and Competitive Landscape - The company is facing increased competition in the domestic pharmaceutical market due to intensified resource concentration and international economic challenges[134]. - The company plans to enhance its market competitiveness by implementing a "one product, one strategy" approach to stabilize the market and expand sales[135]. - The company aims to focus on product technology innovation and improve digital capabilities to drive future growth[110]. Audit and Oversight - The company has established an audit committee consisting of three independent non-executive directors, responsible for overseeing the fairness of financial reporting and internal controls[92]. - The audit committee met four times during the year to review financial statements and discuss audit matters, ensuring thorough oversight[92]. - The total audit fees for the company in 2022 amounted to RMB 1,177,358.48, compared to RMB 1,167,924.51 in 2021, reflecting a slight increase[91].